Charlotte Jones-Burton
Director/Board Member chez BLUEBIRD BIO, INC.
Fortune : 23 759 $ au 31/03/2024
Profil
Charlotte Jones-Burton is the founder of Women of Color in Pharma.
She is currently an Independent Director at bluebird bio, Inc. .
She previously worked as the VP, Global Head-Clinical Development & Nephrology at Otsuka Pharmaceutical Development & Commercialization, Inc. and as the VP-Global Clinical Development & Head-Nephrology at Otsuka Pharmaceuticals (U.K.) Ltd.
In 2022, she held the position of Senior VP-Product Development & Strategy at Chinook Therapeutics, Inc. Dr. Jones-Burton completed her undergraduate studies at Washington University in St. Louis.
She also obtained graduate and doctorate degrees from the University of Maryland School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
BLUEBIRD BIO, INC.
0,01% | 16/06/2023 | 18 562 ( 0,01% ) | 23 759 $ | 31/03/2024 |
Postes actifs de Charlotte Jones-Burton
Sociétés | Poste | Début |
---|---|---|
BLUEBIRD BIO, INC. | Director/Board Member | 07/03/2022 |
Women of Color in Pharma | Founder | - |
Anciens postes connus de Charlotte Jones-Burton
Sociétés | Poste | Fin |
---|---|---|
CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 02/10/2023 |
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The private company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Corporate Officer/Principal | - |
Otsuka Pharmaceuticals (U.K.) Ltd.
Otsuka Pharmaceuticals (U.K.) Ltd. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceuticals (U.K.) Ltd. operates as an investment holding British company with interests in pharmaceutical preparations. The private company is based in Slough, UK. The CEO of the company is Stewart Pearce. | Corporate Officer/Principal | - |
Formation de Charlotte Jones-Burton
Washington University in St. Louis | Undergraduate Degree |
University of Maryland School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The private company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Health Technology |
Otsuka Pharmaceuticals (U.K.) Ltd.
Otsuka Pharmaceuticals (U.K.) Ltd. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceuticals (U.K.) Ltd. operates as an investment holding British company with interests in pharmaceutical preparations. The private company is based in Slough, UK. The CEO of the company is Stewart Pearce. | Health Technology |
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
Women of Color in Pharma |